News|Articles|June 6, 2025
CGTLive®’s Weekly Rewind – June 6, 2025
Author(s)Noah Stansfield
Review top news and interview highlights from the week ending June 6, 2025.
Advertisement
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Satri-cel Makes Strides in Gastric and Gastroesophageal Junction Cancer
The CAR T-cell therapy showed promise in treating advanced gastric cancer by demonstrating improved survival rates and safety in pivotal trial results.
2. Laura Aguilar MD, PhD, on Evaluating Immunotherapy DOC1021 for Glioblastoma
The chief medical officer of Diakonos Oncology discussed phase 1 data on the company’s autologous dendritic cell immunotherapy.
3. CD19/20-Targeted KITE-363 Elicits Strong Response in LBCL
KITE-363 shows promising results in treating relapsed/refractory large B-cell lymphoma, with high response rates and manageable adverse events.
4. Shahzad Raza, MD, on Evaluating CAR-T NXC-201 in R/R Light Chain Amyloidosis
The hematologist/oncologist at the Cleveland Clinic discussed early results from a clinical trial evaluating the BCMA-directed CAR-T therapy.
5. Iovance Biotherapeutics’ Lifileucel Produces Durable Responses in 5-Year Analysis of Advanced Melanoma Data
The analysis included 153 patients with a median follow-up of 57.8 months.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025
Advertisement
Advertisement